TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29044862
Drug: Vinorelbine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine plus cisplatin chemotherapy
Study: 27942103
Drug: Single-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose treatment (5 mg/kg)
Study: 27942103
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses (1.7 mg/kg three times a day)
Study: 12904894
Drug: Eniluracil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eniluracil (20 mg orally twice daily)
Study: 9356001
Drug: Aerosolized surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized surfactant (palmitoylphosphadidylcholine [DPPC]) 607.5 mg/d for 2 weeks
Study: 3485390
Drug: Lidocaine, 1
Normalized name: Buffered Lidocaine, 1%-8.4% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine, 1 mg/kg intravenously 5 min before aortic unclamping and cardiac reperfusion, followed by infusion at 40 micrograms X kg‐1 X min‐1
Study: 31924544
Drug: OPT-302 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT-302 monotherapy (2 mg)
Study: 31924544
Drug: OPT-302 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT-302 (2 mg) combined with ranibizumab (0.5 mg)
Study: 29633644
Drug: KT‐11 food
Approvals — FDA: no, EMA: no, PMDA: no
Description: KT‐11 food tablet (1.2×10^10 KT‐11 cells)
Study: 29633644
Drug: Placebo food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo food tablet (without KT‐11)
Study: 28689898
Drug: Prednisone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (10 mg/day to 60 mg/day)
Study: 16458545
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg/day)
Study: 28689898
Drug: Prednisone (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (35 mg/day)
Study: 23334732
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg weekly) plus exercise (using ARED)
Study: 23334732
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise plus antiresorptive drug (alendronate)
Study: 22008228
Drug: Metoclopramide (MTCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MTCP) 20 mg IV
Study: 22008228
Drug: Diphenhydramine (DPH)
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine (DPH) 50 mg IV
Study: 8866496
Drug: Idebenone (antioxidant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone (antioxidant and enhancer of oxidative metabolism)
Study: 1473740
Drug: Combination chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination chlorambucil and cisplatin
Study: 1473740
Drug: Sequential chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential chlorambucil followed by cisplatin on treatment failure
Study: 29730918
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Ginseng Rg3
Study: 27114413
Drug: Preoperative dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative dexamethasone (0.15 mg/kg before ESD)
Study: 23015655
Drug: tesamorelin, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesamorelin, 2 mg once daily for 12 months
Study: 30900658
Drug: Transdermal diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal diclofenac patch
Study: 17331931
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (Control)
Study: 16361616
Drug: Paclitaxel 225
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 225 mg/m2/3 h, carboplatin (AUC = 6), tirapazamine 260 mg/m2 (escalated to 330 mg/m2 in cycle 2 if tolerable)
Study: 11532465
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel (LNG/EE)
Study: 9468459
Drug: Diuretic (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (hydrochlorothiazide plus triamterene)
Study: 9468459
Drug: Converting enzyme
Normalized name: Prohormone converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converting enzyme inhibitor (trandolapril)
Study: 9468459
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist (amlodipine, added after 3 months if required)
Study: 8181121
Drug: h-SOD (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: h-SOD (10 mg/kg intravenous bolus followed by 0.2 mg.kg-1.min-1 infusion)
Study: 3310630
Drug: Sucralfate suspension
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate suspension (n = 31)
Study: 31670998
Drug: 17α-hydroxyprogesterone caproate
Normalized name: Hydroxyprogesterone Caproate
DrugBank: Hydroxyprogesterone caproate (DB06789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17α-hydroxyprogesterone caproate (250 mg/IM weekly until 37 weeks' gestation)
Study: 25669920
Drug: Probiotic (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Lactobacillus helveticus and Lactobacillus rhamnosus) low-dose (4 × 10(9) CFU/day)
Study: 25669920
Drug: Probiotic (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Lactobacillus helveticus and Lactobacillus rhamnosus) high-dose (8 × 10(9) CFU/day)
Study: 23889923
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone as an add-on therapy to verapamil
Study: 23889923
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with verapamil
Study: 16231168
Drug: DHEA (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (150 mg b.d. for 7 days)
Study: 8711640
Drug: rhDNase 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase 2.5 mg twice daily for 10 days
Study: 1506213
Drug: Coal tar
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coal tar preparation applied twice weekly for 8 weeks (mode I)
Study: 1506213
Drug: Coal tar
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coal tar preparation applied daily for 8 weeks (mode II)
Study: 1506213
Drug: Coal tar
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coal tar preparation used under occlusion for 30 min every second day for 4 weeks (mode III)
Study: 31006669
Drug: NT-pro-BNP levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-pro-BNP levels above 125 pg/ml, thrombocytopenia, atrial fibrillation/flutter
Study: 20202002
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg/day) for a maximum of 4 weeks
Study: 17703640
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care / Unfractionated heparin
Study: 16385658
Drug: Ketorolac 0.5
Normalized name: KETOROLAC 0.5/PHENYLEPHRINE2.5/PROPARACAINE0.5/TROPICAMIDE 1%OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.5 mg/kg before the induction of anesthesia
Study: 91483
Drug: THC 180-210
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 180-210 mg/day
Study: 91483
Drug: THC 70-90
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 70-90 mg/day
Study: 31120313
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine ointment
Study: 26455190
Drug: TXA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (10 mg/kg) injected intravenously approximately 10 minutes before tourniquet release
Study: 23355148
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose 1 μg kg(‐1) over 10 min, followed by constant intravenous infusion 0.7 μg kg(‐1) h(‐1))
Study: 21393261
Drug: Ultrasound and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound and colour Doppler-guided sclerosing polidocanol injections
Study: 11319482
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (trivalent subvirion vaccine, 15mg of surface antigens)
Study: 7951402
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐estradiol, 50 micrograms/day (Estraderm TTS 50) for 14 days, followed by transdermal combination of 17 beta‐estradiol (50 micrograms/day) and norethisterone acetate (NETA) 250 micrograms/day for the next 14 days (Group A)
Study: 7951402
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐estradiol, 50 micrograms/day (Estraderm TTS 50) for 28 days, adding oral medroxyprogesterone acetate (MPA), 10 mg/day, during the final 14 days (Group B)
Study: 22759088
Drug: Pregabalin treatment
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin treatment for 40 days
Study: 19751459
Drug: Amlodipine (AML)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (AML) + Olmesartan Medoxomil (OM) 5+40 mg/d
Study: 19751459
Drug: Amlodipine (AML)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (AML) + Olmesartan Medoxomil (OM) 10+40 mg/d
Study: 19751459
Drug: Amlodipine (AML)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (AML) + Olmesartan Medoxomil (OM) + Hydrochlorothiazide (HCTZ) 10+40+12.5 mg/d
Study: 19751459
Drug: Amlodipine (AML)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (AML) + Olmesartan Medoxomil (OM) + Hydrochlorothiazide (HCTZ) 10+40+25 mg/d
Study: 8277066
Drug: Intravenous anistreplase
Normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anistreplase (30 U) given at home
Study: 8277066
Drug: Intravenous anistreplase
Normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anistreplase (30 U) given in the hospital
Study: 26370515
Drug: Drug Coated
Normalized name: Drug coated stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Coated Balloon (DCB) angioplasty
Study: 26231519
Drug: High Intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Intensity (HI) - Combination of MI1 and MI2 interventions
Study: 23948351
Drug: Icotinib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib (125 mg, three times per day)
Study: 23948351
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg, once per day)
Study: 18950332
Drug: GA+CP group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA+CP group: GA with sevoflurane, combined with caudal anesthesia of plain Bupivacaine (1.25 ml x kg(‐1) of 0.2%)
Study: 18950332
Drug: GA+CA group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA+CA group: sevoflurane GA combined with caudal anesthesia of epinephrine‐added Bupivacaine (1.25 ml x kg(‐1) of 0.2% Bupivacaine plus 1/200,000 epinephrine)
Study: 31016447
Drug: iohexol 350
Normalized name: iohexol 350 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 350 mg I/ml
Study: 7640102
Drug: iopamidol 370
Normalized name: iopamidol 370 mg iodine/mL (76 %) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopamidol 370 mg I/ml
Study: 2769441
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy for five days followed by acupressure wristbands for five days
Study: 24140326
Drug: Capsicum (2g/cow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsicum (2g/cow daily)
Study: 24140326
Drug: Garlic (2g/cow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic (2g/cow daily)
Study: 24140326
Drug: Phytonutrients (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytonutrients (all treatments)
Study: 20875186
Drug: Carbohydrate-milk protein
Normalized name: milk protein concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-milk protein solution (40 g/l carbohydrate, 25 g/l milk protein)
Study: 20875186
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution (65 g/l carbohydrate)
Study: 19017760
Drug: 54 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 mg/d genistein for 24 weeks
Study: 19017760
Drug: 54 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 mg/d genistein for 24 weeks (normoinsulinemic subgroup)
Study: 19017760
Drug: 54 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 mg/d genistein for 24 weeks (hyperinsulinemic subgroup)
Study: 15104196
Drug: Nasal triamcinolone
Normalized name: triamcinolone Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal triamcinolone acetonide (220 microg once daily) for 6 weeks
Study: 15104196
Drug: No intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intranasal corticosteroid treatment
Study: 9848301
Drug: Triptorelin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (3.75 mg IM)
Study: 8006332
Drug: Tetracycline instillation
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline instillation (100 mg/ml, range: 1-4 ml)
Study: 7249528
Drug: Cimetidine (H2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (H2-receptor antagonist)
Study: 901705
Drug: Cimetidine +
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine + Chlorpheniramine (H1-receptor antagonist)
Study: 31410963
Drug: Experimental arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arm (anticancer therapies)
Study: 31410963
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (anticancer therapies)
Study: 16953985
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2V/2.5 mg MPA daily (1 + 2.5 group)
Study: 16953985
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2V/5 mg MPA daily (1 + 5 group)
Study: 16953985
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E2V/2.5 mg MPA daily (2 + 2.5 group)
Study: 16953985
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E2V/5 mg MPA daily (2 + 5 group)
Study: 16953985
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of ccHRT
Study: 16987360
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1 g every 6 hours)
Study: 16987360
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol (1 g every 6 hours)
Study: 10592405
Drug: Isotrexin (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotrexin (combination of isotretinoin 0.05% and erythromycin 2%)
Study: 7491888
Drug: OB diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OB diet (oat bran bread, 12.5 g beta-glucan/d)
Study: 7491888
Drug: OBE diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE diet (oat bran with beta-glucanase, 3.8 g beta-glucan/d)
Study: 7491888
Drug: B diet
Normalized name: chromocarb diethylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: B diet (barley, 13.0 g beta-glucan/d)
Study: 7491888
Drug: W diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: W diet (wheat flour, 1.2 g beta-glucan/d)
Study: 2344168
Drug: 1% mercuric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% mercuric oxide ophthalmic ointment, treated twice daily for 7 days
Study: 7002691
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 mg bolus followed by 0.1 mg/Kg/die for the next 48 hours in continuous i.v. infusion)
Study: 31690980
Drug: Eluvia Drug-Eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eluvia Drug-Eluting Vascular Stent System
Study: 31690980
Drug: Zilver PTX
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilver PTX Drug-Eluting Peripheral Stent
Study: 31395113
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of oral habits
Study: 28946582
Drug: Shaker exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shaker exercise and conventional dysphagia therapy
Study: 30426133
Drug: Conventional dysphagia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dysphagia therapy
Study: 25622199
Drug: SS plus
Normalized name: BSS Plus
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS plus sertraline
Study: 23710672
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing, and one or more of periodontal surgery, systemically administered amoxicillin + metronidazole or local tetracycline at pockets ≥5 mm
Study: 11395033
Drug: Apo A-IV
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apo A-IV infusion with deuterated leucine over a 15 h time period with hourly feeding; TRL separated by ultracentrifugation; apo A-IV isolated by immunoprecipitation and/or SDS-PAGE.
Study: 11395033
Drug: Apo A-IV
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apo A-IV infusion with deuterated leucine; TRL and plasma apo A-IV residence times (RT) and transport rates (TR) measured.
Study: 9426382
Drug: CHO+ (50g
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO+ (50g carbohydrates, 200 micrograms chromium-picolinate, 20g soluble fibre, 100 mg caffeine)
Study: 3574137
Drug: Aspartame in
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame in solution (3 g)
Study: 3574137
Drug: Aspartame in
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame in capsules (3 g)
Study: 30798084
Drug: Chemotherapy continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy continuation (CT-CONT)
Study: 30798084
Drug: Chemotherapy discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy discontinuation (CT-DISC)
Study: 21256179
Drug: Acetyl-l-Carnitine (3g/day)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-l-Carnitine (3g/day)
Study: 21256179
Drug: Acetyl-l-Carnitine (1g/day)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-l-Carnitine (1g/day)
Study: 19551353
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine ophthalmic emulsion 0.05%
Study: 21397805
Drug: Artificial tear
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tear solution
Study: 15295720
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg daily for one month
Study: 9665097
Drug: Strong black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strong black tea (1600 mL/d)
Study: 9665097
Drug: Fried onions
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fried onions (129 g/d)
Study: 9665097
Drug: Fried onions
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fried onions (129 g/d) repeated treatment
Study: 31621189
Drug: VYC-12 injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: VYC-12 injectable gel
Study: 23820423
Drug: Unilateral laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral laparoscopic ovarian drilling (ULOD) with thermal doses adjusted to the volume of the right ovary (60 J/cm³)
Study: 23820423
Drug: Bilateral laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral laparoscopic ovarian drilling (BLOD) with fixed doses of 600 J per ovary
Study: 19960974
Drug: Bailing Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bailing Capsule (BC) and benazepril
Study: 16520478
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine interventions
Study: 16520478
Drug: Item 4
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Item 4 concerning herbal medicine intervention
Study: 15574604
Drug: 4% amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% amethocaine gel (1 g applied for 30 minutes before vaccination)
Study: 15574604
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g applied for 30 minutes before vaccination)
Study: 10809936
Drug: High-dose rivastigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rivastigmine (6-12 mg/day)
Study: 10809936
Drug: Low-dose rivastigmine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rivastigmine (1-4 mg/day)
Study: 1472143
Drug: terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 120 mg once daily
Study: 6708399
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg fenoterol powder
Study: 31562911
Drug: Probiotic VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic VSL#3 taken just before operation and twice daily up to 15 total doses
Study: 23229869
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg low-dose intrathecal bupivacaine
Study: 23229869
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg standard-dose intrathecal bupivacaine
Study: 10672630
Drug: Caffeine (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (equal to baseline daily caffeine consumption)